Advancing viral vector manufacturing with innovation: the importance of the cell line

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Advancing viral vector manufacturing with innovation: the importance of the cell line

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Many critical parameters must be taken into account when optimizing suspension cell-culture methods for viral vector manufacturing, not least the target vector or therapeutic use. Using high-quality media, transfection reagents, cell lines, plasmids, and other resources is also crucial.

In this webinar, our experts will discuss the importance of the cell line for viral vector manufacturing, a multi-step process that has historically been lengthy and labor-intensive. It will highlight the generation and subcloning process of the serum-free suspension HEK293-SKPT-4G9 cell line as the top candidate.

The webinar will further delve into the transfection optimization DoE’s, providing an overview of virus characterization, including a summary of virus production capabilities for AAV, lentivirus, and adenovirus.

Attend the webinar to:

Gain insights into innovative cell line development for AVV, lentivirus, and adenovirus production
Understand the development of a high performing, monoclonal, suspension HEK293 cell line for cGMP cell banking
Assess the comparison with industry-standard cell lines
Learn about the next steps and future advancements in viral packaging cell line evaluation

Marguerite Campbell

Associate Director, Research and Development at SK pharmteco and Yposkesi

Marguerite Campbell is an experienced cell and molecular biologist with over 25 years of experience in the biotech and pharmaceutical industries, and national labs. In her current role at SK pharmteco, she leads the Upstream Processing team and has played an integral role in the cell line development efforts for viral vector manufacturing. Previously, she was a Senior Scientist at Janssen Pharmaceuticals in the Cell Line Development group which supported the biotherapeutic pipeline for 15+ years, a Scientist at Exelixis focusing on bacterial and baculovirus expression systems, and a Biomedical Researcher at the Joint Genome Institute. She received her MS in Molecular Biology from Temple University.

Brian Tomkowicz

Senior Director, Research and Development at SK pharmteco and Yposkesi

Brian is an accomplished cell and molecular biologist with 15+ years of experience in the biotech and pharmaceutical industries. His career is dedicated to the discovery, development, and delivery of curative cell and gene therapies for human diseases. Currently, he is the Senior Director, Head of Research & Development at SK pharmteco where his research focus is on cell development and viral vector engineering to improve viral vector manufacturing. Prior to SK pharmteco, he was a Senior Principal Investigator at Janssen Pharmaceuticals where he led efforts to support AAV-gene therapy preclinical development for both internal assets and external collaboration. He has a PhD in Microbiology and Molecular Virology from Thomas Jefferson University and a BS in Microbiology from Pennsylvania State University. He completed an academic post-doc at the University of Pennsylvania, under the direction of Dr. Ronald G. Collman.

in 10

Days